Valeant Pharmaceuticals (VRX) Announces Acquisition of Afexa Life Sciences for C$76 Million
Tweet
Share
E-mail
Valeant Pharmaceuticals International, Inc, (NYSE: VRX), announced today that it has agreed to acquire Afexa Life Sciences Inc. for approximately C$76 million.
Under the terms of the agreement, holders of Afexa Common Shares will receive C$0.71 in cash per Common Share, which represents a premium of approximately 30% to Afexa's 30-trading day volume weighted average closing price on the Toronto Stock Exchange.
Under the terms of the agreement, holders of Afexa Common Shares will receive C$0.71 in cash per Common Share, which represents a premium of approximately 30% to Afexa's 30-trading day volume weighted average closing price on the Toronto Stock Exchange.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bernstein on whether Hershey (HSY) could eventually step up to buy Mondelez (MDLZ)
- T. Rowe Price to acquire F/m Investments in fixed income push
- Treasure Global sells shares in two deals worth $6.6M total
Create E-mail Alert Related Categories
Mergers and AcquisitionsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
